Editas Medicine Inc - Company Profile
Powered by 
All the sales intelligence you need on Editas Medicine Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Editas Medicine Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Editas Medicine Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Editas Medicine Inc (Editas Medicine), formerly Gengine Inc, is a clinical stage biotechnology company focused on the development of genome treatments for rare diseases. The company’s major products include gene editing technologies and methodologies such as Sleek and UDiTaS. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. Its products are designed for applications in treating hemoglobinopathies, oncology, and other serious diseases. The company utilizes CRISPR/Cas9 and CRISPR/Cas12a genome editing systems to create a pipeline of medicines. Editas Medicine’s pre-clinical pipeline spans investigational candidates for the treatment of ocular and blood diseases, cancer, and diseases of other organs and tissues. The company collaborates with partners like Bristol-Myers Squibb to advance its cellular therapy assets. Editas Medicine is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
11 Hurley Street, Cambridge, Massachusetts, 02141-2110
Website
www.editasmedicine.com
Telephone
1 617 4019000
No of Employees
87
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EDIT (NASD)
Revenue (2024)
$40.5M
25.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
32.5%
(2024 vs 2023)
Market Cap*
$612.4M
Net Profit Margin (2024)
XYZ
46.2%
(2024 vs 2023)
* As of and is in US$
Editas Medicine Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Editas |
| EDIT-401 | Sleek |
| Hemoglobin-Opathies: | UDiTaS |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
Competitor Comparison
| Key Parameters | Editas Medicine Inc | Sanofi | Vertex Pharmaceuticals Inc | Sarepta Therapeutics Inc | Beam Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | France | United States of America | United States of America | United States of America |
| City | Cambridge | Paris | Boston | Cambridge | Cambridge |
| State/Province | Massachusetts | Ile-de-France | Massachusetts | Massachusetts | Massachusetts |
| No. of Employees | 87 | 76,493 | 6,400 | 835 | 511 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jessica Hopfield, Ph.D. | Chairman | Executive Board | 2024 | 61 |
| Gilmore O’Neill | President; Chief Executive Officer; Director | Executive Board | 2022 | 61 |
| Amy Parison | Chief Financial Officer; Senior Vice President | Senior Management | 2025 | 40 |
| Linea Aspesi | Executive Vice President; Chief Administrative Officer | Senior Management | 2025 | - |
| Linda C. Burkly, Ph.D. | Chief Scientific Officer\Senior Management | Senior Management | 2023 | 69 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer